2 weeks Ago By ABMN Staff
Akoya Biosciences, Inc. ( NASDAQ:AKYA – Get Free Report ) was the target of a significant decline in short interest during the month of September. As of September 15th, there was short interest totalling 3,090,000 shares, a decline of 6.
4% from the August 31st total of 3,300,000 shares. Based on an average daily volume of 182,500 shares, the short-interest ratio is currently 16.9 days.
Approximately 14.0% of the shares of the company are sold short. Hedge Funds Weigh In On Akoya Biosciences Large investors have recently made changes to their positions in the business.
Vanguard Group Inc. grew its position in Akoya Biosciences by 3.3% during the 1st quarter.
Vanguard Group Inc. now owns 1,454,288 shares of the company’s stock worth $6,821,000 after purchasing an additional 46,131 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in Akoya Biosciences by 28.
4% in the 4th quarter. Parkman Healthcare Partners LLC now owns 674,787 shares of the company’s stock worth $3,293,000 after buying an additional 149,164 shares during the last quarter. Silvercrest Asset Management Group LLC acquired a new stake in Akoya Biosciences in the 1st quarter worth about $2,724,000.
CIBC Asset Management Inc boosted its holdings in shares of Akoya Biosciences by 176.0% during the 4th quarter. CIBC Asset Management Inc now owns 115,644 shares of the company’s stock worth $564,000 after purchasing an additional 73,737 shares during the last quarter.
Finally, Bank of New York Mellon Corp boosted its holdings in shares of Akoya Biosciences by 16.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock worth $158,000 after purchasing an additional 9,429 shares during the last quarter.
79.42% of the stock is owned by institutional investors and hedge funds. Analyst Ratings Changes AKYA has been the topic of a number of recent research reports.
Craig Hallum dropped their price target on Akoya Biosciences from $7.50 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th.
Piper Sandler decreased their target price on Akoya Biosciences from $6.00 to $4.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th.
JPMorgan Chase & Co. cut Akoya Biosciences from an “overweight” rating to a “neutral” rating in a report on Tuesday, August 6th. BTIG Research cut Akoya Biosciences from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th.
Finally, Morgan Stanley cut Akoya Biosciences from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $4.00 to $3.00 in a report on Tuesday, August 6th.
Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $6.
56. Akoya Biosciences Trading Down 4.9 % Shares of AKYA stock opened at $2.
72 on Tuesday. Akoya Biosciences has a 12-month low of $1.88 and a 12-month high of $6.
31. The company has a current ratio of 2.73, a quick ratio of 1.
98 and a debt-to-equity ratio of 3.43. The stock’s 50-day moving average price is $2.
49 and its 200-day moving average price is $2.95. The stock has a market capitalization of $134.
33 million, a price-to-earnings ratio of -1.85 and a beta of 1.35.
Akoya Biosciences ( NASDAQ:AKYA – Get Free Report ) last announced its earnings results on Monday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.
27). The business had revenue of $23.16 million during the quarter, compared to analyst estimates of $23.
61 million. Akoya Biosciences had a negative return on equity of 126.38% and a negative net margin of 64.
74%. During the same quarter in the previous year, the business earned ($0.51) earnings per share.
Equities research analysts predict that Akoya Biosciences will post -0.98 EPS for the current fiscal year. Akoya Biosciences Company Profile ( Get Free Report ) Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa.
The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. Read More Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
